(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 April 2010 (29.04.2010)

PCT

(10) International Publication Number
WO 2010/046337 A3

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/EP2009/063655

(22) **International Filing Date**:
19 October 2009 (19.10.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/107,085 21 October 2008 (21.10.2008) US

(71) **Applicant** *(for all designated States except US)*: **DOMANTIS LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) **Inventor; and**
(75) **Inventor/Applicant** *(for US only)*: **DE WILDT, Rudolf, Maria** [NL/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

(74) **Agents**: **FURLONG, Isla, Jane** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
1 July 2010

(54) **Title**: LIGANDS THAT HAVE BINDING SPECIFICITY FOR DC-SIGN

(57) **Abstract**: The present invention provides an anti-dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN; CD209) immunoglobulin single variable domain. Polypeptides, ligands and compositions comprising such anti-DC-SIGN immunoglobulin single variable domains are also described along with nucleic acids encoding such immunoglobulins and vectors and host cells for expression. The invention further relates to uses, formulations, compositions and devices comprising such DC-SIGN-binding agents.

WO 2010/046337 A3